Manufacturer of Sacituzumab govitecan

The U.S. Food and Drug Administration (FDA) approved Sacituzumab govitecan for pretreatmentHR+/HER2 metastatic breast cancer, developed by Gilead Sciences Sciences, the first Trop-2-directed ADC to demonstrate overall survival benefit in patients with HR+/HER2 metastatic breast cancer who had previously received endocrine-based therapy and at least two chemotherapy regimens, gosatuzumab now improves survival in pre-treatment HR+/HER2 metastatic breast cancer and second-line metastatic triple-negative breast cancer.

Sacituzumab govitecan is composed of two active ingredients, a monoclonal antibody (a protein) linked to the small molecule SN-38. The monoclonal antibody is designed to recognize and attach to Trop-2, a protein found in many breast cancer cells. Once attached, the drug is taken up by the cells where SN-38 becomes active. SN-38 blocks an enzyme called topoisomerase I, which is involved in copying the cell's DNA needed to make new cells. By blocking this enzyme, cancer cells are prevented from multiplying and eventually die.

Gosatuzumab The original drug has been launched in China, but it has not yet been included in the medical insurance. The price of a 100mg bottle may be around 10,000 yuan, which is relatively expensive. Gosatuzumab Original drug marketed overseas has three versions: European version, American version, and Singapore version. SpecificationsThe price of each 100 mg bottle may be around RMB 10,000-35,000 (the price may fluctuate due to exchange rates). The ingredients of gosatuzumab sold domestically and abroad are basically the same. There is currently no generic version of gosatuzumab available on the market. For specific prices and drug information, please consult your medical consultant.